Drugs / Zimberelimab
Trials 68 · started per year
today
1
4
4
2
7
12
20
7
5
6
2018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04656535 | Apr 2021 → Mar 2026 overdue | glioblastoma | Yale University | Active not recruiting | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT06759649 | Jan 2025 → Nov 2027 expected | cancer | Compugen Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06532565 | Jul 2024 → Jun 2028 expected | cancer | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT04892875 | Dec 2023 → Dec 2025 | hypopharynx squamous cell carcinoma, larynx cancer, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Jennifer Choe | Withdrawn | No outcome recorded |
| Phase 1 | NCT06082960 | Oct 2023 → Dec 2026 expected | cancer | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06045286 | Sep 2023 → Sep 2024 | metastasis from malignant tumor of colon | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05536141 | Oct 2022 → Mar 2029 expected | clear cell renal carcinoma | Arcus Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05007782 | Aug 2021 → Dec 2028 expected | neoplasm | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 1 | NCT04999761 | Jun 2021 → May 2026 overdue | alveolar soft part sarcoma, biliary tract cancer, colorectal cancer, esophageal cancer +4 | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT04772989 | Mar 2021 → Aug 2025 | cervical cancer, diffuse large B-cell lymphoma, esophageal cancer, gastric cancer +4 | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04104672 | Nov 2019 → May 2027 expected | malignant exocrine pancreas neoplasm | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04087018 | Sep 2019 → Jun 2024 | cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03846310 | Apr 2019 → Nov 2024 | non-small cell lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03628677 | Sep 2018 → Jan 2025 | cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03629756 | Jul 2018 → Aug 2021 | breast cancer, castration-resistant prostate carcinoma, colorectal cancer, cutaneous neuroendocrine carcinoma +8 | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03713905 | Jul 2017 → Feb 2022 | cancer | Guangzhou Gloria Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT06238921 | Dec 2024 → Feb 2027 expected | triple-negative breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05978401 | Aug 2023 → Apr 2025 | non-small cell lung carcinoma | Guangzhou Gloria Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05688215 | Mar 2023 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05759312 | Mar 2023 → Feb 2025 | ovarian clear cell cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05419479 | Nov 2022 → May 2026 | pancreatic adenocarcinoma, pancreatic adenosquamous carcinoma | James Cleary, MD, PhD | Suspended | No outcome recorded |
| Phase 1/2 | NCT05909436 | Oct 2022 → Dec 2026 expected | cancer | Guangzhou Gloria Biosciences Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04660812 | May 2021 → Sep 2025 | colorectal cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04381832 | Jul 2020 → Aug 2024 | castration-resistant prostate carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 238 trials | ||||||
| Phase 2 | NCT07424664 | Jun 2026 → Mar 2027 expected | cervical cancer, vaginal neoplasm, vulva cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT07337447 | Apr 2026 → Apr 2029 expected | neuroendocrine carcinoma | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07134556 | Apr 2026 → May 2028 | triple-negative breast carcinoma | MedSIR | Withdrawn | No outcome recorded |
| Phase 2 | NCT07397611 | Mar 2026 → Jan 2028 expected | renal cell carcinoma | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT07283848 | Feb → Dec 2026 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT06790706 | Oct 2025 → Nov 2028 expected | carcinoid tumor, digestive system neuroendocrine neoplasm, gestational trophoblastic neoplasm, peritoneal mesothelioma +2 | Hospices Civils de Lyon | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06250036 | Feb 2025 → Mar 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Royal Marsden NHS Foundation Trust | Recruiting | No outcome recorded |
| Phase 2 | NCT06133517 | Jan 2025 → Jan 2030 expected | infiltrating bladder urothelial carcinoma | Fundación para el Progreso de la Oncología en Cantabria | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06528483 | Dec 2024 → Dec 2026 expected | infiltrating bladder urothelial carcinoma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06048484 | May 2024 → Apr 2027 expected | pancreatic ductal adenocarcinoma | Gulam Manji | Recruiting | No outcome recorded |
| Phase 2 | NCT06048133 | Mar 2024 → Jul 2026 overdue | cholangiocarcinoma | Nataliya Uboha | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06155396 | Jan 2024 → Jun 2027 expected | cervical cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06166589 | Jan 2024 → Jan 2026 overdue | — | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06107114 | Dec 2023 → Nov 2024 | head and neck squamous cell carcinoma | Xuekui Liu | Unknown | No outcome recorded |
| Phase 2 | NCT06128460 | Dec 2023 → Dec 2025 overdue | cervical cancer | Obstetrics & Gynecology Hospital of Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06055738 | Oct 2023 → Dec 2026 expected | cervical cancer | Tang-Du Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06009029 | Aug 2023 → Jul 2026 overdue | pancreatic neoplasm | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05915442 | Jul 2023 → Dec 2026 expected | metastatic prostate carcinoma | Catherine Spina | Recruiting | No outcome recorded |
| Phase 2 | NCT05900765 | Jun 2023 → Jun 2025 | classic Hodgkin lymphoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT05335941 | Jun 2023 → Sep 2027 expected | metastatic malignant neoplasm, urothelial carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05724563 | Jun 2023 → Dec 2027 expected | cholangiocarcinoma, hepatocellular carcinoma | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05886634 | May 2023 → May 2027 expected | dedifferentiated liposarcoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05824468 | May 2023 → Jul 2024 overdue | cervical carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05633667 | Mar 2023 → Sep 2029 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05676931 | Feb 2023 → Dec 2027 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05872724 | Jan 2023 → Jan 2028 expected | cervical cancer | Suzhou Municipal Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05437692 | Jul 2022 → Jul 2024 | cervical cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05632848 | Jun 2022 → Oct 2024 | triple-negative breast carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT05329766 | Jun 2022 → Jan 2027 expected | digestive system cancer | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05024097 | Mar 2022 → Dec 2026 expected | rectal cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 2 | NCT05130177 | Mar 2022 → Feb 2026 overdue | melanoma | Diwakar Davar | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05177770 | Jan 2022 → Apr 2023 | castration-resistant prostate carcinoma | Coherus Oncology, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04791839 | Aug 2021 → Oct 2026 expected | non-small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04736173 | Feb 2021 → May 2027 expected | non-small cell squamous lung carcinoma | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04262856 | May 2020 → Jul 2025 | non-small cell squamous lung carcinoma | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03972722 | May 2019 → May 2022 | cervical cancer | Guangzhou Gloria Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03655483 | Aug 2018 → Apr 2021 | classic Hodgkin lymphoma | Guangzhou Gloria Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03547973 | Aug 2018 → Apr 2030 expected | urothelial carcinoma | Gilead Sciences | Recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07710885 | Jun 2026 → Apr 2030 expected | biliary tract cancer | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06431633 | Feb 2025 → Nov 2031 expected | non-small cell lung carcinoma | Fundación GECP | Recruiting | No outcome recorded |
| Phase 3 | NCT05798819 | May 2023 → May 2025 overdue | — | Guangzhou Gloria Biosciences Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05568095 | Nov 2022 → Jun 2026 overdue | adenocarcinoma | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05502237 | Oct 2022 → Jun 2028 expected | non-small cell lung carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05518318 | Sep 2022 → Jun 2025 | classic Hodgkin lymphoma | Guangzhou Gloria Biosciences Co., Ltd. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05891171 Background | Oct 2023 → Sep 2027 expected | cancer of unknown primary site, cervical cancer, esophageal cancer, gastric cancer +7 | Arcus Biosciences, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05840224 Background | May 2023 → Jul 2026 overdue | cancer | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04747470 Background | Mar 2021 → Nov 2022 | cancer | Gilead Sciences | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06727565 Background | Feb 2025 → Aug 2026 overdue | head and neck squamous cell carcinoma | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04854499 Comparator | Sep 2021 → Oct 2024 | head and neck squamous cell carcinoma | Gilead Sciences | Terminated | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-02 | Gilead Sciences | Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer gilead.com ↗ |
| 2024-06-01 | Gilead Sciences | Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers gilead.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 77 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zimberelimab | “Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.” PMID 37875323 ↗ Dec 202367“Immunotherapy (Zimberelimab) is given every three weeks within one week after the end of high-dose radiotherapy.” NCT06045286 ↗ “GLS-010 (zimberelimab) is a novel, fully human, anti-programmed death-1 monoclonal antibody” PMID 34462189 ↗ Aug 2021 |
| Known as | AB122 | “Zimberelimab (AB122) is a fully human immunoglobulin G4 (hIgG4) monoclonal antibody (mAb) that targets PD-1.” NCT04656535 ↗4“* Zimberelimab (also known as AB122)” NCT05419479 ↗ “Drug: Zimberelimab (AB122)” NCT07134556 ↗ “Zimberelimab (AB122)” NCT05024097 ↗ |
| Known as | GLS-010 | “In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined.” NCT05909436 ↗7“Zimberelimab (GLS-010),240mg d1 iv Q21D” NCT06009029 ↗ |
| Known as | ZIM | “Zimberelimab (ZIM) + Chemotherapy” NCT05502237 ↗ |
| Action | Inhibit | “Zimberelimab is a fully human anti-PD-1 monoclonal antibody.” NCT03629756 ↗ |
| Modality | Monoclonal antibody | “Zimberelimab is a fully human anti-PD-1 monoclonal antibody.” NCT03629756 ↗ |
| Route | Intravenous | “Administered intravenously” NCT03547973 ↗ |
| Target | PDCD1 | “can specially block the PD-1/PD-L1/2 axis” PMID 33691262 ↗ Mar 2021 |